circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
== Medical uses == Cryoneuralysis has been used to relieve pain after thoracotomy, mastectomy, and knee or shoulder arthroplasty. Combined with ultrasound imaging, the procedure can be administered using a hand-held device in an office, and appears to provide an expedient, safe, and nonpharmacological option for treating various chronic pain conditions.
Cement may be created using a countercurrent kiln where the heat is passed in the cement and the exhaust combined, while the incoming air draft is passed along the two, absorbing the heat and retaining it inside the furnace, finally reaching high temperatures. Gasification: the process of creating methane and carbon monoxide from organic or fossil matter, can be done using a counter-current fixed bed ("up draft") gasifier which is built in a similar way to the Anagama kiln, and must therefore withstand more harsh conditions, but reaches better efficiency. In nuclear power plants, water leaving the plant must not contain even trace particles of Uranium. Counter Current Decantation (CCD) is used in some facilities to extract water, totally clear of Uranium.
== Musicians, composers, and lyricists == Burnet Tuthill (1909), musicologist, conductor, founder and secretary of the National Association of Schools of Music Roy Webb (1910), composer for Notorious and Abe Lincoln in Illinois Richard Hale (1914), opera and concert singer; narrator, Peter and the Wolf Oscar Hammerstein II (1916), lyricist for Show Boat, Oklahoma! and The King and I, among other Broadway musical hits Howard Dietz (1917), director of publicity for MGM and lyricist for "Dancing in the Dark" Lorenz Hart (1918), lyricist for Pal Joey and other Broadway musical hits Richard Rodgers* (1923), composer and collaborator with Lorenz Hart and Oscar Hammerstein II; wrote music for Carousel, The Sound of Music, and Victory at Sea, among many others; one of the only two people to have won an Emmy, a Grammy, an Oscar, a Tony Award, and a Pulitzer Prize Elie Siegmeister (1927), composer, music teacher, writer on music Richard Franko Goldman (1930), composer, music professor, president of the Peabody Institute 1969–1977 Milton Katims (1930), conductor, music director of the Seattle Symphony 1954–1976 Mordecai Bauman (1935), baritone Emerson Buckley (1936), conductor, The Crucible, The Ballad of Baby Doe; director of the Florida Grand Opera 1950–1973 Eddie Sauter (1936), jazz musician Elliott Schwartz (1936), composer and professor emeritus of Bowdoin College John La Touche* (1937), lyricist for Cabin in the Sky and The Golden Apple Howard Shanet (1939), conductor and composer, former head of Columbia University's music department Leonard B.
Sources: en.wikipedia.org
Wilson pleaded no contest to the assault and was sentenced in 2010 to two years in prison. In 2017, when The Wolf of Wall Street producer Red Granite Pictures was involved in the 1Malaysia Development Berhad scandal, DiCaprio turned over the gifts he received from business associates at the production company, including from fugitive businessman Jho Low, to the US government. These included a Best Actor Oscar trophy won by Marlon Brando, a $3.2 million Pablo Picasso painting, and a $9 million Jean-Michel Basquiat collage.
Other scientists have stated that this allegation of venom glands "has had the effect of underestimating the variety of complex roles played by oral secretions in the biology of reptiles, produced a very narrow view of oral secretions and resulted in misinterpretation of reptilian evolution". According to these scientists "reptilian oral secretions contribute to many biological roles other than to quickly dispatch prey". These researchers concluded, "Calling all in this clade venomous implies an overall potential danger that does not exist, misleads in the assessment of medical risks, and confuses the biological assessment of squamate biochemical systems." Evolutionary biologist Schwenk says that even if the lizards have venom-like proteins in their mouths they may be using them for a different function, and he doubts venom is necessary to explain the effect of a Komodo dragon bite, arguing that shock and blood loss are the primary factors. Although the mouths of Komodo dragons have been confirmed to contain venom glands with venom in them, it is not clear whether this venom has any serious effect on prey, as opposed to the damage caused by the bite itself. As of 2023, no clear unambiguous evidence of Komodo dragon bites having serious venom effects has been presented. A 2025 histochemical characterisation of the venom glands of the Komodo dragon confirmed the presence of several types of toxins, though the authors note that a venom depositing and draining structure has yet to be identified in lizard teeth, and stress that their study is restricted by specimen availability.
The Altran Foundation for Innovation is a vehicle of social action of the group Altran Technologies. Created in 1996, its main focus is promoting technological innovation for human benefit. One of the ways it does this is by holding an international scientific competition with a new theme every year, rewarding leaders of innovative technology-oriented projects.
Sources: en.wikipedia.org
== Long-term potentiation == Calcium/ calmodulin dependent protein kinase II is also heavily implicated in long-term potentiation (LTP) – the molecular process of strengthening active synapses that is thought to underlie the processes of memory. It is involved in many aspects of this process. LTP is initiated when the NMDA receptors are in a local environment with a voltage potential high enough to displace the positively-charged Mg2+ ion from the channel pore. As a result of the channel being unblocked, Ca2+ ions are able to enter into the postsynaptic neuron through the NMDA receptor channel. This Ca2+ influx activates CaMKII. It has been shown that there is an increase in CaMKII activity directly in the post synaptic density of dendrites after LTP induction, suggesting that activation is a direct result of stimulation.
== Future devices == Currently, Medtronic has the following research and development projects in its pipeline: Next Generation REAL-Time Continuous Glucose Monitoring System; Next Generation Insulin Pump; Pre-filled Insulin Reservoirs; Implantable Insulin Pump; and Artificial pancreas (Semi-Automated System & Closed-Loop System). The industry trend in portable devices has piggybacked on the success of wireless technology but not on the success of other disciplines, such as dynamical system, Cybernetics and adaptive systems, for root cause solutions
The South African government was angered by this escalation of the war, and withdrew its military and diplomatic support for the Rhodesian regime. Pressure from South Africa led Prime Minister Smith to accept the principle of black majority rule in Rhodesia in September 1976. The Selous Scouts unsuccessfully attempted to assassinate Joshua Nkomo, the leader of ZIPRA, while he was in Zambia. While the attacks made outside of Rhodesia by the Selous Scouts were usually militarily successful, they worsened the country's political position. This was because they resulted in civilians and members of the armed forces in the neighbouring countries being killed.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.